Shawn Leung

Chairman, Executive Director & CEO, SinoMab BioScience Limited

Continuously innovating for necessity, Shawn Leung has been on a hunt for solutions to address the unmet medical needs of various chronic and debilitating diseases. One of these needs is antibodies for autoimmune diseases and cancers. Through literature reviews and countless experimentations, his team developed a humanisation technology known as “framework-patching” that improves the safety of antibodies for human use. The team also identified targets in the immune system, and employed the technology to develop antibodies that could modulate the disease conditions for rheumatoid arthritis patients via a completely novel mechanism of action. His therapeutic antibodies are seen to ultimately improve the health conditions and quality of life of millions of patients suffering from these serious ailments.

“Innovation stems from the desire to find a solution through perseverance and hard work.”